Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial

• Carlo A. Gaillard ,

  * E-mail: c.a.j.m.gaillard@umcg.nl

  Affiliation Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

  ⨯
• Andreas H. Bock,

  Affiliation Department of Nephrology, Kantonsspital, Aarau, Switzerland

  ⨯
• Fernando Carrera,

  Affiliation Department of Dialysis, Eurodial, DaVita, Leiria, Portugal

  ⨯
• Kai-Uwe Eckardt,

  Affiliation Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany

  ⨯
• David B. Van Wyck,

  Affiliation Clinical Support Services, Davita Healthcare Partners, Denver, CO, United States of America

  ⨯
• Sukhvinder S. Bansal,

  Affiliation Institute of Pharmaceutical Science, King’s College, London, United Kingdom

  ⨯
• Maureen Cronin,

  Affiliation Vifor Pharma Ltd, Glattbrugg, Switzerland

  ⨯
• Yvonne Meier,

  Affiliation Vifor Pharma Ltd, Glattbrugg, Switzerland

  ⨯
• Sylvain Larroque,

  Affiliation Vifor Pharma Ltd, Glattbrugg, Switzerland

  ⨯
• Simon D. Roger,

  Affiliation Renal Research, Gosford, NSW, Australia

  ⨯
• Iain C. Macdougall

  Affiliation Department of Renal Medicine, King’s College Hospital, London, United Kingdom

  ⨯